# 04_QA_REPORT.md

# Quality Assurance Report

---

# Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0153 |
| Population Package | PP-0153 |
| Title | HDGC-like Families |
| Version | 1.0.0 |
| Status | PASS |

---

# 1. Content QA

| Criterion | Result |
|---|---|
| Single post-testing clinical question | PASS |
| Formal HDGC-like definition included | PASS |
| CDH1/CTNNA1-negative requirement included | PASS |
| Confirmed diffuse gastric cancer requirement included | PASS |
| Additional gastric/lobular breast cancer requirement included | PASS |
| FDR/second-degree requirement included | PASS |
| Risk uncertainty included | PASS |
| Surveillance consideration included | PASS |
| Surveillance timing included | PASS |
| Two-year annual surveillance framework included | PASS |
| Interval-prolongation principle included | PASS |
| Negative-endoscopy interpretation included | PASS |
| RRTG boundary included | PASS |
| Future reassessment boundary included | PASS |

---

# 2. Clinical QA

| Criterion | Result |
|---|---|
| NCI HDGC PDQ prioritized | PASS |
| IGCLC 2020 definition preserved | PASS |
| HDGC-like not treated as molecular diagnosis | PASS |
| Negative CDH1/CTNNA1 testing correctly framed | PASS |
| Confirmed diffuse gastric cancer requirement preserved | PASS |
| Additional gastric/lobular breast cancer requirement preserved | PASS |
| Family-degree requirement preserved | PASS |
| Gastric-cancer risk uncertainty preserved | PASS |
| “May be considered” surveillance wording preserved | PASS |
| Age 40 / 10 years-before-earliest-case framework preserved | PASS |
| Minimum age 18 boundary preserved | PASS |
| Annual surveillance for at least 2 years preserved | PASS |
| Interval prolongation conditionality preserved | PASS |
| No automatic RRTG with negative endoscopy | PASS |
| CDH1-positive management not extrapolated | PASS |

---

# 3. Educational QA

| Criterion | Result |
|---|---|
| Plain-language framing | PASS |
| Clinical phenotype versus genetic diagnosis distinguished | PASS |
| Negative testing uncertainty explained | PASS |
| Risk uncertainty clearly visible | PASS |
| Common misconceptions addressed | PASS |
| No deterministic language | PASS |
| No individualized surveillance plan | PASS |
| No individualized surgery recommendation | PASS |

---

# 4. Governance QA

| Criterion | Result |
|---|---|
| CKO completed | PASS |
| Knowledge Passport completed | PASS |
| Evidence Package completed | PASS |
| QA Report completed | PASS |
| Gold Specification v1.0 followed | PASS |
| Approved Decision Batch implemented | PASS |
| Scope not reopened after approval | PASS |
| Evidence traceability documented | PASS |
| Knowledge Graph documented | PASS |
| Boundary/overlap declared | PASS |
| Versioning complete | PASS |

---

# 5. Boundary / Overlap QA

## PP-0152 — HDGC Genetic Testing Criteria

PP-0152 owns:

- pre-test eligibility;
- exact HDGC testing criteria;
- testing pathway.

PP-0153 owns:

- post-testing HDGC-like state;
- unresolved hereditary risk;
- surveillance/management boundary.

**Result: PASS**

## PP-0149 — HDGC

PP-0149 owns:

- established HDGC;
- CDH1-associated risk;
- HDGC clinical management.

PP-0153 owns:

- genetically unresolved HDGC-like families.

**Result: PASS**

## PP-0150 — CDH1

PP-0150 owns:

- CDH1 gene;
- pathogenic variants;
- result interpretation.

PP-0153 only uses CDH1 status as part of the HDGC-like definition.

**Result: PASS**

## PP-0151 — CTNNA1

PP-0151 owns:

- CTNNA1 gene;
- pathogenic variants;
- evidence limitations.

PP-0153 only uses CTNNA1 status as part of the definition.

**Result: PASS**

## Gastric Cancer Screening / Endoscopy

Detailed endoscopy and biopsy methodology remains delegated.

PP-0153 owns only the high-level indication and timing framework relevant to HDGC-like families.

**Result: PASS**

## Risk-Reducing Surgery

PP-0153 owns the **boundary** that RRTG is not advised when endoscopies are negative in HDGC-like families because risk is uncertain.

Detailed surgery belongs to the dedicated surgical architecture.

**Result: PASS**

---

# 6. Clinical Safety QA

| Safety Item | Result |
|---|---|
| HDGC-like not presented as confirmed genetic diagnosis | PASS |
| No individual gastric-cancer risk calculation | PASS |
| No individualized surveillance schedule | PASS |
| No automatic RRTG recommendation | PASS |
| No CDH1-positive risk extrapolation | PASS |
| Negative genetic testing not treated as absolute reassurance | PASS |
| Negative endoscopy not treated as proof of no hereditary risk | PASS |
| No unsupported repeat-testing interval | PASS |
| Risk uncertainty explicitly preserved | PASS |

---

# 7. Evidence Traceability QA

Primary:

- NCI Hereditary Diffuse Gastric Cancer (PDQ®)
- IGCLC 2020 framework as summarized by NCI

Supporting:

- NCI Genetics of Gastric Cancer (PDQ®)
- NCI Cancer Genetics Risk Assessment and Counseling (PDQ®)
- relevant project guideline materials

The formal definition and surveillance/RRTG boundaries are directly grounded in the NCI HDGC PDQ.

---

# 8. Scope Integrity QA

### Correctly Included

- HDGC-like definition;
- negative CDH1/CTNNA1 status;
- diffuse gastric cancer requirement;
- additional gastric/lobular breast cancer;
- FDR/second-degree requirement;
- risk uncertainty;
- surveillance consideration;
- surveillance timing;
- interval prolongation;
- negative-endoscopy boundary;
- RRTG boundary.

### Correctly Excluded

- CDH1 result interpretation;
- CTNNA1 result interpretation;
- CDH1-positive penetrance;
- detailed endoscopy/biopsy;
- surgical technique;
- detailed breast surveillance;
- detailed genetic counseling;
- unrelated hereditary syndromes.

**Result: PASS**

---

# 9. Knowledge Graph QA

### Pre-test

**PP-0152**
→ testing criteria

### Gene-level

**PP-0150**
→ CDH1

**PP-0151**
→ CTNNA1

### Post-test unresolved state

**PP-0153**
→ HDGC-like

### Parent clinical framework

**PP-0149**
→ HDGC

### Supporting clinical branches

→ Gastric Cancer Screening / Endoscopy  
→ Risk-Reducing Surgery  
→ Genetic Counseling

**Result: PASS**

---

# 10. Gold Artifact QA

| Artifact | Present | Status |
|---|---|---|
| 01_CKO.md | Yes | PASS |
| 02_KNOWLEDGE_PASSPORT.md | Yes | PASS |
| 03_PRIMARY_EVIDENCE_PACKAGE.md | Yes | PASS |
| 04_QA_REPORT.md | Yes | PASS |

---

# 11. Final QA Decision

# PASS

PP-0153 satisfies the locked Gold Population Package requirements.

The package preserves the critical clinical distinction:

**PP-0152 = WHO SHOULD BE TESTED?**

↓

**PP-0153 = WHAT IF THE FAMILY REMAINS HDGC-LIKE DESPITE NEGATIVE TESTING?**

↓

**Risk uncertain → surveillance may be considered → negative endoscopy does not justify automatic RRTG**

No unsupported genetic cause, risk estimate, surveillance interval, or surgical indication has been introduced.

---

# Final Status

**APPROVED — GOLD / QA PASS**
